 |
Top 39 medical and healthcare startups in Seattle
Oct 31, 2025 | By Jason Kwon | 15 |
1
Funding: $372.5M
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
3
Funding: $951.3M
Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients. It's deploying a platform that can repair and control genes in cells or replace any cell in the body.
Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients. It's deploying a platform that can repair and control genes in cells or replace any cell in the body.
4
Funding: $515M
Truveta is a healthcare data platform collaboration with physicians, life science researchers, and others in the healthcare community.
Truveta is a healthcare data platform collaboration with physicians, life science researchers, and others in the healthcare community.
5
Funding: $363M
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
6
Funding: $299.3M
98point6 combines deep technology with the expertise of board-certified physicians to provide text-based primary care anytime, anywhere.
98point6 combines deep technology with the expertise of board-certified physicians to provide text-based primary care anytime, anywhere.
7
Funding: $261.3M
Impel NeuroPharma is a medical device company developing a novel drug delivery device that uses direct nose-to-brain delivery.
Impel NeuroPharma is a medical device company developing a novel drug delivery device that uses direct nose-to-brain delivery.
8
Funding: $247M
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.
9
Funding: $215M
Tune Therapeutics develops epigenomic controls that dial gene expression up or down to potentially thwart cancers, genetic diseases and aging.
Tune Therapeutics develops epigenomic controls that dial gene expression up or down to potentially thwart cancers, genetic diseases and aging.
10
Funding: $187M
Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
11
Funding: $177M
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases.
GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases.
12
Funding: $145M
DexCare provides a Platform-as-a-Service offering to manage health system capacity and demand across all lines of care.
DexCare provides a Platform-as-a-Service offering to manage health system capacity and demand across all lines of care.
13
Funding: $135.6M
Tasso is revolutionizing diagnostics by creating technologies for blood sample collection that place the user at the center of process. Our wearable blood collection system, the HemoLinkTM, is being developed to improve the user experience as well as enable both healthcare consumers and providers with convenient access to reliable laboratory test results.
Tasso is revolutionizing diagnostics by creating technologies for blood sample collection that place the user at the center of process. Our wearable blood collection system, the HemoLinkTM, is being developed to improve the user experience as well as enable both healthcare consumers and providers with convenient access to reliable laboratory test results.
14
Funding: $130.1M
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
15
Funding: $120M
Aurion Biotechnologies is on mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases.
Aurion Biotechnologies is on mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases.
16
Funding: $95.5M
Vera Whole Health delivers primary care, acute care, and health coaching via on or near-site clinics.
Vera Whole Health delivers primary care, acute care, and health coaching via on or near-site clinics.
17
Funding: $93M
Bonum Therapeutics technology platform can be used to treat a variety of diseases, including oncology.
Bonum Therapeutics technology platform can be used to treat a variety of diseases, including oncology.
18
Funding: $85.1M
Proprio uses machine learning, computer vision, and augmented reality user interfaces to improve the accuracy and efficiency of surgery.
Proprio uses machine learning, computer vision, and augmented reality user interfaces to improve the accuracy and efficiency of surgery.
19
Funding: $71M
Vilya is a biotechnology company that plans to design novel artificial molecules with customized biologic-like properties that can hit difficult-to-drug therapeutic targets in a broad set of indications.
Vilya is a biotechnology company that plans to design novel artificial molecules with customized biologic-like properties that can hit difficult-to-drug therapeutic targets in a broad set of indications.
20
Funding: $67M
Immunexpress, a molecular diagnostics company, developed a product pipeline to address the unmet clinical needs of sepsis patients, as well as the professional needs of clinicians, payers, and healthcare systems.
Immunexpress, a molecular diagnostics company, developed a product pipeline to address the unmet clinical needs of sepsis patients, as well as the professional needs of clinicians, payers, and healthcare systems.
